Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High dose cytarabine: a review.

B J Bolwell1, P A Cassileth, R P Gale

  • 1Hematology-Oncology Section, University of Pennsylvania School of Medicine, Philadelphia.

Leukemia
|May 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection.

Bone marrow transplantation·2017
Same author

Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.

Bone marrow transplantation·2016
Same author

Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2015
Same author

Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients.

Bone marrow transplantation·2015
Same author

Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.

Leukemia·2015
Same author

Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2014

High-dose cytarabine (HDARAC) shows promise in treating hematologic malignancies, including acute myelogenous leukemia and acute lymphocytic leukemia. While effective, potential cerebellar toxicity in older patients requires careful consideration.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • High-dose cytarabine (HDARAC) is increasingly utilized for hematologic malignancies.
  • Standard cytarabine doses are effective, but HDARAC offers comparable or superior efficacy in certain leukemias.
  • HDARAC can induce remissions in patients resistant to conventional chemotherapy.

Purpose of the Study:

  • To review the efficacy and toxicity of high-dose cytarabine (HDARAC) in treating various hematologic malignancies.
  • To evaluate HDARAC's role in acute myelogenous leukemia, acute lymphocytic leukemia, and other hematologic cancers.
  • To discuss the potential benefits and limitations of HDARAC therapy.

Main Methods:

  • Review of recent clinical data and studies on HDARAC therapy.

Related Experiment Videos

  • Analysis of efficacy in remission induction and long-term survival.
  • Assessment of HDARAC's activity in central nervous system leukemia and prophylaxis.
  • Evaluation of toxicity profiles, particularly cerebellar damage.

    • Main Results:

    • HDARAC demonstrates comparable or greater efficacy than standard doses in acute myelogenous leukemia remission induction.
    • HDARAC can achieve remissions in patients refractory to conventional cytarabine doses.
    • Intravenous HDARAC effectively treats central nervous system leukemia and may provide CNS prophylaxis in acute lymphocytic leukemia.
    • HDARAC shows activity in advanced non-Hodgkin lymphomas and chronic myelogenous leukemia in acute phase.

    Conclusions:

    • HDARAC is an active agent in various hematologic malignancies, including leukemias and lymphomas.
    • HDARAC offers potential for improved long-term outcomes, though further controlled trials are needed.
    • Cerebellar toxicity is a dose-limiting side effect, particularly in patients over 50 years old.
    • Combination therapy with HDARAC may enhance therapeutic results, warranting further investigation in randomized trials.